Drug intelligence / Profile preview

amiparen

Development stage
Unknown
Lead developer
Otsuka Pharmaceutical Factory, Inc.
Modality
Small Molecules
Administration
Intravenous
01

Overview

Amiparen is a balanced amino acid injection solution developed by Otsuka Pharmaceutical Factory, primarily indicated for parenteral nutritional support. It contains a comprehensive profile of 18 essential and non-essential amino acids, including branched-chain amino acids (BCAAs) such as L-leucine, L-isoleucine, and L-valine, formulated to maintain nitrogen balance and promote protein synthesis in patients with impaired oral or enteral intake. Beyond its established role in clinical nutrition, Amiparen is being investigated for its potential to prevent postoperative acute kidney injury (AKI) in patients undergoing high-risk vascular surgeries, such as thoracic or thoracoabdominal aortic aneurysm repair. The proposed mechanism for renal protection involves amino acid-induced renal vasodilation and increased glomerular filtration rate (GFR), which may enhance the kidney's resilience to perioperative ischemic stress.

Brand names
AmiparenAmiparen-10Amiparen10Amiparen 10Amiparen-5Amiparen5Amiparen 5
Other names
Amino Acids Injection10% Amino Acid Injection
02

Targets

SERPINA1 (Alpha-1-antitrypsin)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on amiparen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amiparen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call